Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis

Otavio Cabral-Marques, Gabriela Riemekasten*

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Systemic sclerosis (SSc) is a connective tissue disorder of unknown etiology characterized by the presence of multiple autoantibodies, including those against angiotensin and endothelin receptors. Patients with SSc can develop heterogeneous clinical manifestations including microvascular damage, the dysregulation of innate and adaptive immunity, and generalized fibrosis of multiple organs. Autoantibodies against angiotensin II type I receptor (AT1R) and endothelin-1 type A receptor (ETAR) play important roles in the pathogenesis of SSc. These autoantibodies regulate physiological processes ranging from production of collagen by skin fibroblasts to angiogenesis modulation. Understanding the mechanisms behind autoantibodies against AT1R and ETAR could provide insight to future novel therapies for SSc patients. In this review, we focus on elucidating the immunopathological mechanisms triggered by anti-AT1R and anti-ETAR autoantibodies to summarize current knowledge about vascular abnormalities resulting in progressive damage of organs seen in patients with SSc.

OriginalspracheEnglisch
ZeitschriftAutoimmunity Reviews
Jahrgang15
Ausgabenummer7
Seiten (von - bis)690-694
Seitenumfang5
ISSN1568-9972
DOIs
PublikationsstatusVeröffentlicht - 01.07.2016

Fördermittel

We acknowledge all the patients and their families for their participation in our studies. We thank Dr. Anja Kerstein, Dr. Antje Mueller, and Dr. Barbara Russo all from the Department of Rheumatology–University of Lübeck and Dr. Jing Sun. from the Institute for Systemic Inflammation Research–University of Lübeck for proofreading. In addition, we thank the support and funding from the intramural grant of the University of Lübeck, German Systemic Sclerosis Network (DNSS) , DFG grant RI 1056-11-1/2 , Actelion Pharmaeutical GmbH Germany, GSK, CellTrend, Scleroderma Foundation, and MirjamLichy Foundation.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren